Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.47% | -95.13% | -91.41% | -38.63% | 258.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.47% | -95.13% | -91.41% | -38.63% | 258.77% |
| Cost of Revenue | -99.27% | -96.45% | -94.13% | -81.60% | -10.37% |
| Gross Profit | -99.61% | -92.41% | 103.78% | 218.88% | 450.22% |
| SG&A Expenses | -64.07% | -64.32% | -61.86% | -33.40% | 2.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -92.16% | -84.40% | -88.70% | -72.36% | -8.02% |
| Operating Income | -106.93% | 55.61% | 83.70% | 126.41% | 283.48% |
| Income Before Tax | -110.91% | 73.21% | 80.50% | 112.55% | 219.80% |
| Income Tax Expenses | -- | 100.00% | 264.71% | -- | -- |
| Earnings from Continuing Operations | -110.91% | 73.17% | 80.36% | 112.53% | 219.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.91% | 73.17% | 80.36% | 112.53% | 219.71% |
| EBIT | -106.93% | 55.61% | 83.70% | 126.41% | 283.48% |
| EBITDA | -106.63% | 60.66% | 84.08% | 132.98% | 300.80% |
| EPS Basic | -108.34% | 78.90% | 89.19% | 106.31% | 162.53% |
| Normalized Basic EPS | -106.63% | 61.28% | 89.34% | 110.54% | 192.61% |
| EPS Diluted | -108.41% | 78.91% | 89.10% | 106.13% | 161.95% |
| Normalized Diluted EPS | -106.68% | 61.28% | 89.34% | 110.45% | 191.86% |
| Average Basic Shares Outstanding | 30.82% | 27.18% | 81.68% | 98.55% | 91.43% |
| Average Diluted Shares Outstanding | 29.77% | 27.18% | 81.68% | 100.39% | 92.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |